THOMAS SHAVER: Open Payments
NPI 1790120137 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$595 in 12 payments from 7 companies in 2025. Trend: 2023 $660 · 2024 $815 · 2025 $595
Food & beverage: $595
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
| Neurocrine BioSciences, Inc. | 1 | $149 |
| E.R. Squibb & Sons, L.L.C. | 4 | $75 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
| ABBVIE INC. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: CAPLYTA, INVEGA SUSTENNA, INGREZZA, COBENFY, UZEDY, VRAYLAR, REXULTI.
Industry payments across DC — which companies pay providers there.
